Phospho-HTRA2 (S212) Antibody

What is the biological significance of HtrA2 S212 phosphorylation?

HtrA2 (High temperature requirement protein A2), also known as Omi, is a serine protease that plays a critical role in apoptosis and stress response. Phosphorylation at S212 is biologically significant as it represents a key regulatory mechanism that modulates HtrA2's protease activity and proapoptotic function. Research demonstrates that Akt1 and AKT2 phosphorylate mitochondria-released HtrA2 at serine-212 both in vivo and in vitro, which directly inhibits its serine protease activity . This phosphorylation event represents an important post-translational modification that switches HtrA2 from a pro-apoptotic to an anti-apoptotic state, effectively promoting cell survival by preventing HtrA2-mediated cell death . Understanding this phosphorylation is crucial for researchers investigating apoptotic pathways, cancer biology, and neurodegenerative disorders where dysregulation of cell death mechanisms plays a significant role.

How does HtrA2 contribute to apoptotic signaling pathways?

HtrA2 contributes to apoptosis through both caspase-dependent and caspase-independent mechanisms:

Caspase-dependent pathway:

• Upon apoptotic stimuli, HtrA2 is released from mitochondria into the cytosol

• Released HtrA2 binds to inhibitor of apoptosis proteins (IAPs), particularly XIAP

• This binding antagonizes IAP inhibition of caspase activity, promoting apoptosis

Caspase-independent pathway:

• HtrA2's intrinsic serine protease activity directly contributes to cell death

• The protease activity is able to cleave various cellular substrates independent of caspase activation

Importantly, the proapoptotic function of HtrA2 is closely tied to its protease activity, which is regulated by phosphorylation at specific residues, including S212. When phosphorylated at S212 by Akt, HtrA2's ability to cleave IAPs (including XIAP and c-IAP) is inhibited, preventing its proapoptotic function while maintaining its binding to these proteins . This regulatory mechanism creates a fine balance between cell survival and cell death pathways.

What are the recommended applications for Phospho-HTRA2 (S212) antibodies?

Based on current commercial offerings and research literature, Phospho-HTRA2 (S212) antibodies are recommended for the following applications:

It's important to note that the antibody specificity is crucial, as it should detect HtrA2 only when phosphorylated at S212 and not cross-react with non-phosphorylated forms or other phosphorylation sites. Most commercially available Phospho-HTRA2 (S212) antibodies are validated for these applications, but researchers should always perform their own validation experiments for their specific experimental conditions .

What are the common species reactivity patterns for Phospho-HTRA2 (S212) antibodies?

Commercially available Phospho-HTRA2 (S212) antibodies typically demonstrate reactivity with the following species:

The high degree of conservation in the HtrA2 sequence around the S212 phosphorylation site contributes to this cross-species reactivity. When selecting an antibody for your research, it's advisable to choose one that has been specifically validated for your species of interest. For less common model organisms, preliminary validation experiments should be conducted before proceeding with large-scale studies .

What are the optimal sample preparation methods for detecting phosphorylated HtrA2 at S212?

For optimal detection of phosphorylated HtrA2 at S212, researchers should consider the following sample preparation guidelines:

Cell/Tissue Lysis:

• Use phosphatase inhibitor cocktails in all buffers to prevent dephosphorylation during sample preparation

• Include protease inhibitors to prevent degradation of the target protein

• For mitochondrial HtrA2, consider using mitochondrial isolation protocols before lysis

• Lysis buffers containing 1% NP-40 or RIPA buffer are commonly used

For Western Blotting:

• For optimal separation, use 10-12% SDS-PAGE gels

• Expect to detect a band at approximately 36 kDa for processed/mature HtrA2

• Transfer conditions: wet transfer at 100V for 90 minutes or overnight at 30V at 4°C

For Immunoprecipitation:

• Pre-clear lysates with Protein A/G beads to reduce background

• Incubate cleared lysates with Phospho-HTRA2 (S212) antibody overnight at 4°C

• Use gentle washing conditions to maintain phospho-epitope integrity

For Immunohistochemistry:

• Use freshly prepared 4% paraformaldehyde-fixed tissues

• Antigen retrieval using citrate buffer (pH 6.0) is recommended

• Block with appropriate blocking solution containing 5% normal serum

These methods help ensure maximum retention of the phosphorylation at S212 during sample preparation, which is critical for accurate detection and quantification of this post-translational modification.

How can researchers design experiments to validate Phospho-HTRA2 (S212) antibody specificity?

Validating the specificity of Phospho-HTRA2 (S212) antibodies is crucial for ensuring reliable experimental results. The following approaches are recommended:

Phosphatase Treatment Control:

• Split your sample into two portions

• Treat one portion with lambda phosphatase to remove phosphate groups

• The signal should disappear in phosphatase-treated samples when probed with phospho-specific antibodies

• The total HtrA2 signal should remain unchanged in both samples

Phospho-null and Phosphomimetic Mutants:

• Generate expression constructs with S212A (non-phosphorylatable) and S212D (phosphomimetic) mutations

• Transfect cells with these constructs

• Phospho-S212 antibody should not recognize S212A mutant but may recognize endogenous phosphorylated HtrA2

• This approach tests antibody specificity for the phospho-site

Akt Inhibition/Activation:

• Treat cells with Akt inhibitors (such as MK-2206) to reduce S212 phosphorylation

• Alternatively, activate Akt using growth factors or genetic approaches

• Confirm Akt activation/inhibition by blotting for phospho-Akt

• Monitor changes in HtrA2 S212 phosphorylation levels

Peptide Competition:

• Pre-incubate the antibody with excess phospho-S212 peptide before immunoblotting

• This should abolish or significantly reduce the signal if the antibody is specific

• As a control, pre-incubation with non-phosphorylated peptide should not affect signal

These validation approaches ensure that the observed signals truly represent HtrA2 phosphorylated at S212, minimizing the risk of experimental artifacts or misinterpretation of results.

How do different phosphorylation sites on HtrA2 (S212 vs S400) affect its function differently?

HtrA2 undergoes phosphorylation at multiple sites, with S212 and S400 being the most well-characterized. These phosphorylation events have distinct functional consequences:

S212 Phosphorylation (Akt-mediated):

• Directly inhibits HtrA2's protease activity

• Does not disrupt binding to IAPs but prevents cleavage of XIAP and c-IAP

• Promotes cell survival by suppressing HtrA2's proapoptotic function

• Akt phosphorylation of HtrA2 represents a pro-survival mechanism in cancer cells

S400 Phosphorylation (CDK5-mediated):

• Involved in maintaining mitochondrial membrane potential under stress conditions

• Important for mitochondrial function and confers stress protection

• Phosphorylation occurs in a p38-dependent manner

• Associated with neuroprotection, particularly relevant to neurodegenerative diseases like Parkinson's disease

Understanding these distinct phosphorylation events is crucial for developing targeted therapeutic approaches that modulate HtrA2 activity in different disease contexts, such as cancer (where inhibiting S212 phosphorylation might promote apoptosis) or neurodegenerative diseases (where enhancing S400 phosphorylation might be neuroprotective).

What are the implications of HtrA2 S212 phosphorylation in cancer research?

The phosphorylation of HtrA2 at S212 has significant implications for cancer research, particularly in understanding mechanisms of apoptosis resistance:

Cell Survival Mechanism:

• Akt-mediated phosphorylation at S212 inhibits HtrA2's proapoptotic function

• This inhibition may contribute to cancer cell survival and resistance to apoptotic stimuli

• Hyperactivation of Akt in many cancers may promote HtrA2 S212 phosphorylation

Therapeutic Target Potential:

• Blocking S212 phosphorylation could potentially restore HtrA2's proapoptotic function

• This represents a potential strategy to sensitize cancer cells to chemotherapy

• Combining Akt inhibitors with conventional chemotherapeutics might enhance therapeutic efficacy

Experimental Approaches for Cancer Research:

• Use phospho-HtrA2 (S212) antibodies to assess phosphorylation status in tumor samples

• Compare S212 phosphorylation levels between normal and tumor tissues

• Investigate correlation between S212 phosphorylation levels and patient outcomes

• Test the effect of Akt inhibitors on S212 phosphorylation and cancer cell survival

Research Finding:
In experimental models, non-phosphorylatable HtrA2-S212A induces more apoptosis than wild-type HtrA2, while phosphomimetic HtrA2-S212D inhibits programmed cell death induced by DNA damage agents (STS and VP16) . This suggests that the phosphorylation status at S212 could serve as a biomarker for apoptosis resistance and potentially as a predictor of therapy response in cancer patients.

How can phosphomimetic and phospho-null mutations be utilized to study HtrA2 S212 phosphorylation?

Phosphomimetic and phospho-null mutations are powerful tools for studying the functional consequences of HtrA2 S212 phosphorylation:

Phospho-null Mutation (S212A):

• Substitutes serine with alanine, which cannot be phosphorylated

• Mimics the permanently non-phosphorylated state of HtrA2

• Useful for studying the consequences of preventing S212 phosphorylation

• Research shows that S212A mutants retain serine protease activity and induce more apoptosis than wild-type HtrA2

Phosphomimetic Mutation (S212D/E):

• Substitutes serine with aspartic acid (D) or glutamic acid (E)

• The negative charge mimics the phosphorylated state

• Simulates constitutively phosphorylated HtrA2

• Studies demonstrate that S212D mutants lose protease activity and inhibit programmed cell death induced by DNA damage agents

Experimental Applications:

• Stable Cell Lines: Generate cell lines stably expressing wild-type, S212A, or S212D HtrA2 to study long-term effects

• Apoptosis Assays: Compare apoptotic responses between cells expressing different HtrA2 variants when challenged with apoptotic stimuli

• Protease Activity Assays: Directly measure and compare the protease activity of purified recombinant wild-type, S212A, and S212D HtrA2 proteins

• Protein-Protein Interaction Studies: Investigate how phosphorylation status affects HtrA2 interactions with binding partners like IAPs

• In vivo Models: Generate knock-in mouse models expressing S212A or S212D to study physiological consequences

These mutational approaches circumvent limitations of pharmacological manipulation of kinases (which may have off-target effects) and allow direct assessment of the specific role of S212 phosphorylation in various cellular processes and disease models.

What is the relationship between HtrA2 phosphorylation and neurodegenerative diseases?

HtrA2 has been implicated in several neurodegenerative diseases, with its phosphorylation status playing a crucial regulatory role:

Parkinson's Disease (PD):

• Mutations in the HtrA2 gene have been identified in PD patients

• Loss of function mutations in the HtrA2 gene are associated with Parkinson's disease

• HtrA2 knockout mice display a neurodegenerative phenotype resembling PD with loss of neurons in the striatum

• This suggests HtrA2 may have a neuroprotective function rather than just apoptotic roles

Phosphorylation Significance:

• While S212 phosphorylation (by Akt) is primarily associated with inhibiting apoptotic functions, phosphorylation at S400 (by CDK5) is particularly relevant in neurodegeneration

• Phosphorylation at S400 is involved in maintaining mitochondrial membrane potential under stress conditions and is important for mitochondrial function

• Mutations adjacent to phosphorylation sites (S142 and S400) have been found in Parkinson's disease patients

• A rare likely-pathogenic mutation (T242M) has been identified that alters mitochondrial homeostasis due to loss of GSK-3β-mediated phosphorylation on HtrA2, leading to uncontrolled cell death with PD phenotype

HtrA2 in Other Neurodegenerative Conditions:

• Selective downregulation of HtrA2 has been linked to neuronal death in Huntington's disease

• The neuroprotective activity of HtrA2 is associated with its protease activity

Understanding these relationships suggests that modulating HtrA2 phosphorylation could be a potential therapeutic strategy for neurodegenerative diseases. Researchers studying these conditions should consider examining both S212 and S400 phosphorylation patterns in their experimental models to fully understand HtrA2's role in neurodegeneration.

How can Phospho-HTRA2 (S212) antibodies be used in neurodegenerative disease research?

Phospho-HTRA2 (S212) antibodies offer valuable tools for investigating the role of HtrA2 phosphorylation in neurodegenerative diseases:

Tissue Analysis Applications:

• Immunohistochemistry of brain tissues from patients with neurodegenerative diseases to assess phosphorylation status

• Comparison of phospho-HtrA2 (S212) levels between affected and unaffected brain regions

• Correlation of phosphorylation patterns with disease progression or severity

Cellular Models:

• Detection of altered phosphorylation in neuronal cell models expressing disease-associated mutations

• Monitoring changes in phosphorylation status during oxidative stress or mitochondrial dysfunction

• Assessing the impact of neuroprotective compounds on HtrA2 phosphorylation

Experimental Protocol for Brain Tissue Analysis:

• Prepare paraffin-embedded brain tissue sections (5-7 μm thickness)

• Perform antigen retrieval using citrate buffer (pH 6.0)

• Block with 5% normal serum in PBS containing 0.3% Triton X-100

• Incubate with Phospho-HTRA2 (S212) antibody (1:100-1:300 dilution) overnight at 4°C

• Apply appropriate detection system (HRP or fluorescence-based)

• Counterstain and mount for imaging

• Quantify phospho-HtrA2 staining intensity relative to total HtrA2

Research Applications:

• Investigating whether disease-modifying treatments affect HtrA2 phosphorylation status

• Examining the relationship between Akt activation and HtrA2 phosphorylation in disease models

• Studying potential crosstalk between different HtrA2 phosphorylation sites (S212, S400) in the context of neurodegeneration

These approaches can help elucidate whether dysregulation of HtrA2 phosphorylation contributes to neurodegenerative processes and potentially identify new therapeutic targets for these devastating conditions.

What are common troubleshooting issues when working with Phospho-HTRA2 (S212) antibodies?

When working with Phospho-HTRA2 (S212) antibodies, researchers may encounter several technical challenges that can affect experimental outcomes:

Issue: Weak or No Signal

• Possible causes:

  • Rapid dephosphorylation during sample preparation

  • Insufficient antigen retrieval (for IHC)

  • Low abundance of phosphorylated protein

• Solutions:

  • Ensure phosphatase inhibitors are fresh and used at appropriate concentrations

  • Optimize antigen retrieval conditions (time, temperature, buffer)

  • Consider enrichment strategies (immunoprecipitation before Western blotting)

  • Increase antibody concentration or incubation time

Issue: High Background

• Possible causes:

  • Non-specific binding

  • Excessive antibody concentration

  • Insufficient blocking

• Solutions:

  • Increase blocking time/concentration

  • Reduce primary antibody concentration

  • Use more stringent washing conditions

  • Consider using a different blocking agent (BSA vs. milk vs. normal serum)

Issue: Cross-reactivity

• Possible causes:

  • Antibody recognizing non-phosphorylated HtrA2 or other phosphorylated proteins

  • Insufficient specificity of the antibody

• Solutions:

  • Validate with phospho-null controls (S212A mutant or phosphatase-treated samples)

  • Use peptide competition assays

  • Consider testing alternative antibody clones or suppliers

Issue: Inconsistent Results Between Experiments

• Possible causes:

  • Variations in cell culture conditions affecting phosphorylation levels

  • Inconsistent sample preparation

  • Antibody degradation

• Solutions:

  • Standardize culture conditions and treatments

  • Develop a consistent protocol for sample collection and processing

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Include positive controls in each experiment

Careful attention to these technical considerations can significantly improve the reliability and reproducibility of experiments using Phospho-HTRA2 (S212) antibodies across different applications and experimental systems.

What controls should be included when using Phospho-HTRA2 (S212) antibodies?

Incorporating appropriate controls is essential for ensuring the validity of results obtained with Phospho-HTRA2 (S212) antibodies:

Essential Controls for Western Blotting:

Controls for Immunohistochemistry/Immunofluorescence:

• Negative control: Primary antibody omission

• Peptide competition: Pre-incubation of antibody with phospho-peptide should abolish specific signal

• Phosphatase treatment: Treating one section with lambda phosphatase should eliminate phospho-specific staining

• Dual staining: Co-staining with total HtrA2 antibody to confirm localization patterns

Genetic/Molecular Controls:

• S212A mutant-expressing cells as negative control

• S212D mutant-expressing cells as a reference for the phosphorylated state

• siRNA knockdown of HtrA2 to confirm antibody specificity

Treatment Controls:

• Cells treated with apoptotic stimuli should show changes in phosphorylation status

• Akt activators/inhibitors to modulate phosphorylation levels at S212

• Time-course experiments to capture dynamic changes in phosphorylation

What emerging research areas involve Phospho-HTRA2 (S212)?

Several promising research directions are emerging related to HtrA2 S212 phosphorylation:

Cancer Therapeutics:

• Targeting the Akt-HtrA2 phosphorylation axis to enhance apoptosis in cancer cells

• Developing small molecules that can prevent S212 phosphorylation specifically

• Investigating combination therapies that target both HtrA2 phosphorylation and IAP proteins

Neurodegenerative Disease Mechanisms:

• Exploring the interplay between different HtrA2 phosphorylation sites (S212, S400) in neuronal survival

• Investigating whether S212 phosphorylation status affects neuronal resilience to stress

• Examining potential crosstalk between HtrA2 and other Parkinson's disease-associated proteins

Mitochondrial Biology:

• Understanding how S212 phosphorylation affects HtrA2's role in mitochondrial protein quality control

• Investigating the relationship between mitochondrial dynamics and HtrA2 phosphorylation

• Exploring how cellular stress affects the subcellular distribution and phosphorylation of HtrA2

Novel Detection Methods:

• Development of phospho-specific nanobodies for live-cell imaging of HtrA2 phosphorylation

• Application of proximity ligation assays to study HtrA2 interactions dependent on phosphorylation state

• Mass spectrometry-based approaches to quantify stoichiometry of multiple phosphorylation events

Therapeutic Modulation:

• Screening for compounds that specifically modulate HtrA2 phosphorylation

• Development of cell-penetrating peptides that can interfere with kinase-substrate interactions

• Exploring RNA-based therapeutics targeting kinases responsible for HtrA2 phosphorylation

These emerging areas highlight the continuing importance of Phospho-HTRA2 (S212) antibodies as essential tools for advancing our understanding of cellular processes and developing potential therapeutic strategies for various diseases.

How might proteomics approaches enhance studies of HtrA2 phosphorylation?

Advanced proteomics methodologies offer powerful approaches to study HtrA2 phosphorylation beyond traditional antibody-based techniques:

Phosphoproteomics Strategies:

• Global Phosphoproteome Analysis:

  • Identifies changes in the phosphorylation landscape during apoptosis or stress

  • Places HtrA2 phosphorylation in the broader context of cellular signaling networks

  • Can reveal previously unknown phosphorylation sites on HtrA2

• Targeted Mass Spectrometry (MS):

  • Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM) for precise quantification

  • Can measure the stoichiometry of phosphorylation at multiple sites simultaneously (S212 and S400)

  • Provides absolute quantification of phosphorylated vs. non-phosphorylated forms

• Phosphopeptide Enrichment Techniques:

  • IMAC (Immobilized Metal Affinity Chromatography)

  • TiO₂ (Titanium Dioxide) enrichment

  • Phospho-specific antibody-based enrichment

  • These methods increase detection sensitivity for low-abundance phosphorylation events

Integrative Approaches:

• Phosphorylation Dynamics:

  • Pulse-chase SILAC experiments to determine turnover rates of phosphorylated HtrA2

  • Time-resolved phosphoproteomics following stimulation or inhibition of relevant kinases

• Multi-omics Integration:

  • Combining phosphoproteomics with interactomics to identify phosphorylation-dependent protein interactions

  • Correlating transcriptomics data with changes in HtrA2 phosphorylation

• Structural Proteomics:

  • Hydrogen-deuterium exchange MS to understand conformational changes induced by phosphorylation

  • Crosslinking MS to map interactions affected by S212 phosphorylation

Methodological Workflow for HtrA2 Phosphorylation Analysis:

• Cell stimulation with appropriate treatments (e.g., apoptotic stimuli, Akt activators/inhibitors)

• Protein extraction with phosphatase inhibitors

• Digestion with specific proteases (trypsin, chymotrypsin)

• Phosphopeptide enrichment

• LC-MS/MS analysis using high-resolution instruments

• Data analysis with specialized software for phosphosite identification and quantification

• Validation of key findings with orthogonal methods (e.g., Phospho-HTRA2 antibodies)